GSTM1 and chronic kidney disease: Regardless of the Hb cut-off, the proportion of eligible patients actually treated with ESAs was low (≤ 15.5%), although the proportion treated increased across the CKD stages (from < 10% in stage 3a to approximately 40% in stage 5).